Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Identifieur interne : 002937 ( PubMed/Corpus ); précédent : 002936; suivant : 002938Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Auteurs : Carolina Scagnolari ; Elisa Vicenzi ; Francesca Bellomi ; Maria Giuseppina Stillitano ; Debora Pinna ; Guido Poli ; Massimo Clementi ; Ferdinando Dianzani ; Guido AntonelliSource :
- Antiviral therapy [ 1359-6535 ] ; 2004.
English descriptors
- KwdEn :
- Animals, Chlorocebus aethiops, Drug Synergism, GTP-Binding Proteins (genetics), GTP-Binding Proteins (metabolism), Humans, Interferon Type I (genetics), Interferon Type I (pharmacology), Interferon-gamma (genetics), Interferon-gamma (pharmacology), Myxovirus Resistance Proteins, Recombinant Proteins (pharmacology), SARS Virus (drug effects), SARS Virus (physiology), Vero Cells, Virus Replication (drug effects).
- MESH :
- chemical , genetics : GTP-Binding Proteins, Interferon Type I, Interferon-gamma.
- chemical , metabolism : GTP-Binding Proteins.
- chemical , pharmacology : Interferon Type I, Interferon-gamma, Recombinant Proteins.
- drug effects : SARS Virus, Virus Replication.
- physiology : SARS Virus.
- Animals, Chlorocebus aethiops, Drug Synergism, Humans, Myxovirus Resistance Proteins, Vero Cells.
Abstract
There is currently an urgent need to identify effective antiviral agents that will prevent and treat severe acute respiratory syndrome coronavirus (SARS-CoV) infection. In this study, we have investigated and compared the antiviral effect of different interferons (IFNs) on SARS-CoV replication in the epithelial kidney monkey Vero cell line. The results showed that SARS-CoV grown in Vero cells is moderately sensitive to IFN-beta and only weakly sensitive to IFN-alpha and IFN-gamma, in comparison to other IFN-sensitive viruses, such as those for encephalomyocarditis, vesicular stomatitis and Newcastle disease. Simultaneous incubation of Vero cells with IFN-beta and IFN-gamma indicated that they may act synergistically against SARS-CoV replication. The IFN-induced MxA protein was detected in the IFN-treated Vero cells. The data, however, suggest that the antiviral activity of IFN against SARS-CoV virus is independent of MxA expression.
PubMed: 15651759
Links to Exploration step
pubmed:15651759Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.</title><author><name sortKey="Scagnolari, Carolina" sort="Scagnolari, Carolina" uniqKey="Scagnolari C" first="Carolina" last="Scagnolari">Carolina Scagnolari</name><affiliation><nlm:affiliation>Department of Exerimental Medicine and Pathology--Virology section, University La Sapienza, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Vicenzi, Elisa" sort="Vicenzi, Elisa" uniqKey="Vicenzi E" first="Elisa" last="Vicenzi">Elisa Vicenzi</name></author><author><name sortKey="Bellomi, Francesca" sort="Bellomi, Francesca" uniqKey="Bellomi F" first="Francesca" last="Bellomi">Francesca Bellomi</name></author><author><name sortKey="Stillitano, Maria Giuseppina" sort="Stillitano, Maria Giuseppina" uniqKey="Stillitano M" first="Maria Giuseppina" last="Stillitano">Maria Giuseppina Stillitano</name></author><author><name sortKey="Pinna, Debora" sort="Pinna, Debora" uniqKey="Pinna D" first="Debora" last="Pinna">Debora Pinna</name></author><author><name sortKey="Poli, Guido" sort="Poli, Guido" uniqKey="Poli G" first="Guido" last="Poli">Guido Poli</name></author><author><name sortKey="Clementi, Massimo" sort="Clementi, Massimo" uniqKey="Clementi M" first="Massimo" last="Clementi">Massimo Clementi</name></author><author><name sortKey="Dianzani, Ferdinando" sort="Dianzani, Ferdinando" uniqKey="Dianzani F" first="Ferdinando" last="Dianzani">Ferdinando Dianzani</name></author><author><name sortKey="Antonelli, Guido" sort="Antonelli, Guido" uniqKey="Antonelli G" first="Guido" last="Antonelli">Guido Antonelli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15651759</idno><idno type="pmid">15651759</idno><idno type="wicri:Area/PubMed/Corpus">002937</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002937</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.</title><author><name sortKey="Scagnolari, Carolina" sort="Scagnolari, Carolina" uniqKey="Scagnolari C" first="Carolina" last="Scagnolari">Carolina Scagnolari</name><affiliation><nlm:affiliation>Department of Exerimental Medicine and Pathology--Virology section, University La Sapienza, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Vicenzi, Elisa" sort="Vicenzi, Elisa" uniqKey="Vicenzi E" first="Elisa" last="Vicenzi">Elisa Vicenzi</name></author><author><name sortKey="Bellomi, Francesca" sort="Bellomi, Francesca" uniqKey="Bellomi F" first="Francesca" last="Bellomi">Francesca Bellomi</name></author><author><name sortKey="Stillitano, Maria Giuseppina" sort="Stillitano, Maria Giuseppina" uniqKey="Stillitano M" first="Maria Giuseppina" last="Stillitano">Maria Giuseppina Stillitano</name></author><author><name sortKey="Pinna, Debora" sort="Pinna, Debora" uniqKey="Pinna D" first="Debora" last="Pinna">Debora Pinna</name></author><author><name sortKey="Poli, Guido" sort="Poli, Guido" uniqKey="Poli G" first="Guido" last="Poli">Guido Poli</name></author><author><name sortKey="Clementi, Massimo" sort="Clementi, Massimo" uniqKey="Clementi M" first="Massimo" last="Clementi">Massimo Clementi</name></author><author><name sortKey="Dianzani, Ferdinando" sort="Dianzani, Ferdinando" uniqKey="Dianzani F" first="Ferdinando" last="Dianzani">Ferdinando Dianzani</name></author><author><name sortKey="Antonelli, Guido" sort="Antonelli, Guido" uniqKey="Antonelli G" first="Guido" last="Antonelli">Guido Antonelli</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="ISSN">1359-6535</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Drug Synergism</term><term>GTP-Binding Proteins (genetics)</term><term>GTP-Binding Proteins (metabolism)</term><term>Humans</term><term>Interferon Type I (genetics)</term><term>Interferon Type I (pharmacology)</term><term>Interferon-gamma (genetics)</term><term>Interferon-gamma (pharmacology)</term><term>Myxovirus Resistance Proteins</term><term>Recombinant Proteins (pharmacology)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Vero Cells</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>GTP-Binding Proteins</term><term>Interferon Type I</term><term>Interferon-gamma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>GTP-Binding Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Interferon Type I</term><term>Interferon-gamma</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Drug Synergism</term><term>Humans</term><term>Myxovirus Resistance Proteins</term><term>Vero Cells</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is currently an urgent need to identify effective antiviral agents that will prevent and treat severe acute respiratory syndrome coronavirus (SARS-CoV) infection. In this study, we have investigated and compared the antiviral effect of different interferons (IFNs) on SARS-CoV replication in the epithelial kidney monkey Vero cell line. The results showed that SARS-CoV grown in Vero cells is moderately sensitive to IFN-beta and only weakly sensitive to IFN-alpha and IFN-gamma, in comparison to other IFN-sensitive viruses, such as those for encephalomyocarditis, vesicular stomatitis and Newcastle disease. Simultaneous incubation of Vero cells with IFN-beta and IFN-gamma indicated that they may act synergistically against SARS-CoV replication. The IFN-induced MxA protein was detected in the IFN-treated Vero cells. The data, however, suggest that the antiviral activity of IFN against SARS-CoV virus is independent of MxA expression.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15651759</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1359-6535</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>6</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Antiviral therapy</Title><ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation></Journal><ArticleTitle>Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.</ArticleTitle><Pagination><MedlinePgn>1003-11</MedlinePgn></Pagination><Abstract><AbstractText>There is currently an urgent need to identify effective antiviral agents that will prevent and treat severe acute respiratory syndrome coronavirus (SARS-CoV) infection. In this study, we have investigated and compared the antiviral effect of different interferons (IFNs) on SARS-CoV replication in the epithelial kidney monkey Vero cell line. The results showed that SARS-CoV grown in Vero cells is moderately sensitive to IFN-beta and only weakly sensitive to IFN-alpha and IFN-gamma, in comparison to other IFN-sensitive viruses, such as those for encephalomyocarditis, vesicular stomatitis and Newcastle disease. Simultaneous incubation of Vero cells with IFN-beta and IFN-gamma indicated that they may act synergistically against SARS-CoV replication. The IFN-induced MxA protein was detected in the IFN-treated Vero cells. The data, however, suggest that the antiviral activity of IFN against SARS-CoV virus is independent of MxA expression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scagnolari</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Exerimental Medicine and Pathology--Virology section, University La Sapienza, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicenzi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bellomi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Stillitano</LastName><ForeName>Maria Giuseppina</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Pinna</LastName><ForeName>Debora</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Poli</LastName><ForeName>Guido</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Clementi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dianzani</LastName><ForeName>Ferdinando</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Guido</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antivir Ther</MedlineTA><NlmUniqueID>9815705</NlmUniqueID><ISSNLinking>1359-6535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579071">MX1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064547">Myxovirus Resistance Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D019204">GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019204" MajorTopicYN="N">GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064547" MajorTopicYN="N">Myxovirus Resistance Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15651759</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002937 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002937 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15651759
|texte= Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15651759" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |